Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tianyin Pharmaceutical, which specializes in traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API), is set to expand the formulation for its product Gingko Mihuan Oral Liquid (GMOL).
Subscribe to our email newsletter
GMOL is used in China to treat brain ischemia and infarction, coronary heart diseases, memory dysfunction and other neurological disorders.
Gingko extracts mainly comprise flavonoids and terpenoids.
Flavonoids consist of ginkgoflavone glycoside which are antioxidants that reduce capillary fragility observed in cardiovascular disorders.
Terpenoids consist of ginkgolides and bilobalide that inhibit platelet activating factor (PAF) which in consequence reduce the blood viscosity.
GMOL also contains extracts from Gastrodia elata for treating neurological symptoms like epilepsy, headaches, dizziness and memory dysfunction.
According to the company, the new capsule formulation will reduce the overall cost of sales by 70% while extending the expiration period to 3 years from the existing 2 years.